2023-509316-28-00CompletedPhase 1
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- First submitted
- 29 Jan 2024
- Start date
- 6 May 2024
- Lead sponsor
- Sanofi-Aventis Recherche & Developpement
- EU CT number
- 2023-509316-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 128
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.